People · Operator
Named in public records as an officer, director or promoter · active 2017–2019 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Harpoon Therapeutics, Inc. | — | Biotechnology | Series D+ | $220.3M | $1.4B | 2017 |
| Aura Biosciences, Inc. | — | Biotechnology | Series C | $198.2M | $2.5B | 2017 |
Mark E. Chin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark E. Chin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Johnson | 1 | 35 |
| Peter B. Finn | 1 | 11 |
| Alan Colowick | 1 | 7 |
| Casper Breum | 1 | 5 |
| Lawrence C. Best | 1 | 4 |
| Mark Chin | 1 | 4 |
| Luke Walker | 1 | 3 |
| Pedro Granadillo | 1 | 3 |
| Javier Garcia | 1 | 3 |
| Art Pappas | 1 | 3 |
| Alan Walts | 1 | 3 |
| Gerald McMahon | 1 | 3 |
| Peter Wirth | 1 | 3 |
| Ron R. Hunt | 1 | 2 |
| Andrew Robbins | 1 | 2 |
| Henri E. Termeer | 1 | 2 |
| Joseph Bailes | 1 | 2 |
| Casper E. Breum | 1 | 2 |
| Edmundo Muniz, M.D., Ph.D. | 1 | 2 |
| Scott Myers | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.